Engelbertsen Lab

Cardiovascular immunology research lab - Lund University, Sweden

[Engelbertsen Lab @EngelbertsenLab]

Fascinating pre-print article pouring cold water on the notion of human exTregs in general and CD4+CD16+CD56+ exTregs in particular. This debate will be interesting to follow!

[bioRxiv Immunology @biorxiv_immuno]

The quest continues: Human CD4+ CD16+ CD56+ "exTreg" resemble NKT cells instead https://t.co/Pw95vFayC1 #biorxiv_immuno

[DiabetesLUDC @DiabetesLUDC]

Congratulations to LUDC researchers Daniel Engelbertsen and Alexandru Schiopu who have been awarded a grant of SEK five million by The Swedish Heart Lung Foundation @hjartlungfonden 👏 Their project aims to identify treatments that can prevent new heart attacks. #cancer #diabetes

[Engelbertsen Lab @EngelbertsenLab]

The study was supported by @hjartlungfonden, Crafoord Foundation, the Swedish Research Council, Albert Påhlsson Foundation and spearheaded by Megan Mulholland in collaboration with our wonderful collaborators at University of Leiden and Cantargia! @medfak_LU @DiabetesLUDC

[Engelbertsen Lab @EngelbertsenLab]

Our new study ‘Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation’ is now published in Cardiovascular Research (https://t.co/xEFz3W8e46).

[Engelbertsen Lab @EngelbertsenLab]

IL1RAP blockade is being evaluated in clinical trials to limit tumor growth (Nadunolimab) and to treat autoimmune conditions (CAN10). Our work suggests that IL1RAP blockade may limit atherosclerotic disease, but studies in humans are required to evaluate clinical efficacy.

[Lukas Tomas @l_tomas01]

Check out our study at https://t.co/U02MAQoeCn
Great to see this effort with @BjorkbackaLab and @EngelbertsenLab published and featured as Editor’s Choice.

[Joan_Yuan_Lab @TheYuanLab]

📢the next #LUImmunotalks drops on September 20 with two presentations given by @EngelbertsenLab and @BemarkMats who just moved to @medfak_LU!!! Do not miss @LuWcmm @Lund_Stem

[Engelbertsen Lab @EngelbertsenLab]

Congratulations Megan on this well deserved award! For those attending AAI #immunology23 in Washington DC next month, I recommend stopping by her poster presentation for updates on our work on the role of immune checkpoints in atherosclerosis!

[DiabetesLUDC @DiabetesLUDC]

Congratulations to PhD student Megan Mulholland @EngelbertsenLab at LUDC, who is the winner of the 2022 JACC: CardioOncology young author achievement award. She discusses her research in this podcast episode: https://t.co/odxhdj7CHf
https://t.co/M0CWLoPUN4
@JACCJournals

[Engelbertsen Lab @EngelbertsenLab]

Very happy for the support from @hjartlungfonden which is crucial for our continued studies into mechanisms underlying cardiovascular disease!

[DiabetesLUDC @DiabetesLUDC]

Congratulations to LUDC researcher Daniel Engelbertsen who receives SEK three million from @hjartlungfonden for a research project which will investigate the causes of heart attack and stroke. @svtnyheter visited the @EngelbertsenLab to learn more. https://t.co/uKVaY4Q8hz

[Engelbertsen Lab @EngelbertsenLab]

The study was a multi-site collaboration between our lab, Andrew Lichtman and Annabelle Rodriguez (@HDLHeart). Big thanks to all co-authors! An excellent editorial perspective by @sumanthprabhu01 can be found here: https://t.co/rIkm72fI9r

[Engelbertsen Lab @EngelbertsenLab]

Happy to share our latest study investigating the role of the immune checkpoint molecule LAG3 in experimental atherosclerosis, out now in JACC:Cardiooncology! #JACCJournals #cardiooncology
https://t.co/2uHXol6hTh

[Engelbertsen Lab @EngelbertsenLab]

We demonstrate that genetic loss or antibody-mediated blockade of LAG3 promotes T cell activation and accumulation of T cells in atherosclerotic plaques. This is of particular interest given the recent FDA approval of anti-LAG3/anti-PD1 for treatment of melanoma.

[Anton Gisterå @antongistera]

I am recruiting a PhD student if you know anyone interested in cardiovascular immunology. #research https://t.co/P4FRmQXE5p

[Engelbertsen Lab @EngelbertsenLab]

@l_tomas01 Well done, nice to see so much emphasis on the dynamics! Human translation is difficult, looking forward to someone trying deuterium-labeling in endarterectomy patients to track cells in plaque over time 10.1084/jem.20170355

[Fil Swirski @SwirskiLab]

We are hiring!
(RT please)

@IcahnMountSinai is growing fast and @SinaiHeartBlood is hiring tenure-track Assistant Professors

Are you a
Brilliant
Creative
Productive

Postdoc / Instructor?

Send CV and LOI to me asap

More about us
https://t.co/NTDCR7KQZ8

And what we do

👇

[Atherosclerosis @ATHjournal]

High IL-2Rβγ signalling results in activation of inflammatory and regulatory lymphocytes with a net zero effect on AS and decreased plasma cholesterol levels. Changes in chol. levels are associated with reductions in hepatic LXR-related gene expression
https://t.co/mXN6XyrYKm

[Engelbertsen Lab @EngelbertsenLab]

@cam_phd @SinaiHeartBlood @SinaiBrain Congrats Cameron, well deserved!

[Engelbertsen Lab @EngelbertsenLab]

Re: Swe research funding
"I en annan cirkel finns de som redan har externfinansiering, [..] men där pressen att fortsätta skriva så många ansökningar som möjligt gör att man väljer ”lågt hängande frukter” i stället för en originell forskningsidé."

https://t.co/ITQZ9zBddH

[Engelbertsen Lab @EngelbertsenLab]

Looking forward to the results of Treg-stimulating low-dose IL-2 trials in CVD patients (LILACS trial) and studies investigating the use of IL-2Rbeta agonistic IL-2 (bempegaldesleukin) in patients with solid tumors.
@lunduniversity @DiabetesLUDC @medfak_LU
(2/2)

[Engelbertsen Lab @EngelbertsenLab]

Our recent study of IL-2R signaling in atherosclerosis is available at @ATHjournal! https://t.co/EomklzMDvi
The paper describes the lymphocyte activating and cholesterol modulating effects of IL-2R(beta-gamma) agonisms leading to a net zero effect on atherosclerosis. (1/2)